Bing

SEARCH HISTORY

Several important new application (NDA), supplemental new drug applications (SNDA) and related announcements are expected this month, starting with Incyte’s (NasdaqGS: INCY) SNDA “for ruxolitinib as a potential treatment of patients with …
ETF Trends Setting The Pace · 12/4/2014
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte Corp. (INCY) Tuesday said that phase 3 RA-BEACON study of their Rheumatoid arthritis drug Baricitinib met its primary endpoint. The primary endpoint of the study was to achieve …
Finanznachrichten · 12/9/2014
We manage most of our lives on our smartphones, so why not our finances? The app market has become saturated with apps promising to help you budget better, shop smarter and save more. And experts don’t predict a slowdown in the creation of apps …
Fox Business · 3/28/2014
Eli Lilly‘s (NYSE:LLY) rheumatoid arthritis treatment developed by drug developer Incyte (NASDAQ:INCY) using oral janus-associated kinases, or JAK, inhibitors, has produced positive phase 2b results, according to a company statement. The results were ...
MedCity News · ByStephanie Baum · 6/8/2012
But it goes for the upside as well as the down. TWST: What type of run have the Canadian biotech stocks been having over the past 12-18 months? Dr. Bapty: Well, 18 and 12 are two completely different numbers. The Canadian biotech stocks were on the …
The Wall Street Transcript · 5/6/2002
Health sciences companies are defined as those companies that commit or derive at least 50% of their assets, revenues, or operating profits from the activities just described.
Globe and Mail · 7/30/2015